Future studies should prioritize multicenter randomized controlled designs incorporating dynamic biomarkers (e.g., CD8+ T cell infiltration) to assess tumor immune microenvironment evolution and guide personalized therapy. The gene discussed is CD8A; the disease is neoplasm.